Showing Latest Articles
A randomized, double-blind, placebo-controlled study of the efficacy and safety of bupropion for treating hypoactive sexual desire disorder in ovulating women
BJU International, 02/15/2010
Clinical Article
Safarinejad MR et al. – In response to the GEQ, of patients in the bupropion and placebo groups, 65.3 percent, and 4.3 percent, respectively, responded 'Definitely yes'. Of patients in the bupropion and placebo groups, 71.8 percent, and 3.7 percent, respectively, were definitely satisfied with the efficacy of their treatment. After 12 weeks of treatment, 82 women in the bupropion and five in the placebo group were willing to continue therapy. The results from this study indicate that bupropion SR is an effective and well–tolerated treatment for HSDD in ovulating women. Further controlled trials are warranted.